Streetbeat News

Stock Prices

CRNX

Crinetics Pharmaceuticals announced that it expects its cash and equivalents to be sufficient to fund its current operating plan into 2028.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 9:15 pm

TARS

Tarsus Pharmaceuticals shares are trading higher after the company reported better-than-expected Q2 financial results.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 9:14 pm

SVV

Savers Value Village shares are trading lower after the company reported worse-than-expected Q2 financial results and cut its FY24 net sales guidance below estimates.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 9:14 pm

ORGO

Organogenesis Holdings Inc. (NASDAQ: ORGO) announced that it is on track to submit the Biologics License Application (BLA) for its ReNu product by the end of 2025. The company has completed enrollment in the second Phase 3 clinical trial ahead of expectations, with 594 patients enrolled. The FDA has indicated that two well-controlled Phase 3 trials are required for regulatory approval.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 9:13 pm

ADMA

ADMA Biologics has raised its financial guidance for FY24 and FY25. The company now expects total revenue to exceed $400 million in FY24 and $445 million in FY25, up from previous estimates of $357.504 million and $414.48 million, respectively. Net income and Adjusted EBITDA projections have also been increased.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 9:12 pm

ETON

Eton Pharmaceuticals (NASDAQ:ETON) reported Q2 2024 GAAP EPS of $(0.12), missing the $(0.07) estimate by 71.43%. However, sales of $9.074M beat the $8.800M estimate by 3.11%, despite a 24.36% decrease from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 9:12 pm

PBI

Pitney Bowes shares are trading higher after the company reported better-than-expected Q2 financial results.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 9:12 pm

PHUN

Phunware (NASDAQ:PHUN) reported Q2 2024 GAAP EPS of $(0.32), beating the estimate of $(0.37). However, sales of $1.011M missed the $1.103M estimate and were down 21.93% year-over-year.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 9:12 pm

DNTH

Dianthus Therapeutics (NASDAQ:DNTH) reported Q2 earnings per share (EPS) of $(0.51), beating the analyst estimate of $(0.55) by 7.27%. The company also reported sales of $1.86 million, surpassing the estimate of $322.75 thousand by 477.23%. This marks a significant improvement from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 9:11 pm

ZVRA

ZVRA Therapeutics shares are trading lower following the company's announcement of a proposed public offering of common stock.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 9:11 pm